T1D Silver Bullet? Provention Bio Soars On Hopes Teplizumab Is Type 1 Diabetes Game Changer

10 Jun 2019

• By Sten Stovall

Shares in Provention Bio were pushed sharply higher on Monday after news that a two-week course of its experimental immunotherapy teplizumab dramatically reduced type 1 diabetes diagnosis rates in people at high risk for the disease.

Game changer — Provention Bio Says Teplizumab Represents a ‘Paradigm Shift’ in T1D Treament • Source: Shutterstock

Provention Bio Inc.’s market value soared on Monday after news the US-based biotech’s investigational anti-CD3 monoclonal antibody teplizumab delayed the onset of type 1 diabetes (T1D) in people at high risk – the first time a drug has been able to delay or prevent the disease.

Results from the study, presented at the American Diabetes Association meeting in San Francisco at the weekend, showed that a...